These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21726160)

  • 21. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.
    Foss F; Horwitz SM; Coiffier B; Bartlett N; Popplewell L; Pro B; Pinter-Brown LC; Shustov A; Furman RR; Haioun C; Koutsoukos T; O'Connor OA
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):238-43. PubMed ID: 22542448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.
    O'Connor OA; Hamlin PA; Portlock C; Moskowitz CH; Noy A; Straus DJ; Macgregor-Cortelli B; Neylon E; Sarasohn D; Dumetrescu O; Mould DR; Fleischer M; Zelenetz AD; Sirotnak F; Horwitz S
    Br J Haematol; 2007 Nov; 139(3):425-8. PubMed ID: 17910632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis.
    Hong JY; Yoon DH; Yoon SE; Kim SJ; Lee HS; Eom HS; Lee HW; Shin DY; Koh Y; Yoon SS; Jo JC; Kim JS; Kim SJ; Cho SH; Lee WS; Won JH; Kim WS; Suh C
    Sci Rep; 2019 Dec; 9(1):20302. PubMed ID: 31889144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.
    Grem JL; Kos ME; Evande RE; Meza JL; Schwarz JK
    Cancer; 2015 Nov; 121(21):3862-8. PubMed ID: 26242208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients.
    Lee SS; Jung SH; Ahn JS; Kim YK; Cho MS; Jung SY; Lee JJ; Kim HJ; Yang DH
    J Korean Med Sci; 2016 Jul; 31(7):1160-3. PubMed ID: 27366017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methotrexate and Pralatrexate.
    Wood GS; Wu J
    Dermatol Clin; 2015 Oct; 33(4):747-55. PubMed ID: 26433846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.
    Marchi E; Paoluzzi L; Scotto L; Seshan VE; Zain JM; Zinzani PL; O'Connor OA
    Clin Cancer Res; 2010 Jul; 16(14):3648-58. PubMed ID: 20501616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.
    Maruyama D; Nagai H; Maeda Y; Nakane T; Shimoyama T; Nakazato T; Sakai R; Ishikawa T; Izutsu K; Ueda R; Tobinai K
    Cancer Sci; 2017 Oct; 108(10):2061-2068. PubMed ID: 28771889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.
    Hong X; Song Y; Huang H; Bai B; Zhang H; Ke X; Shi Y; Zhu J; Lu G; Liebscher S; Cai C
    Target Oncol; 2019 Apr; 14(2):149-158. PubMed ID: 30904980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pralatrexate for Peripheral T-Cell Lymphoma (PTCL): Chance Only Supports The Prepared Mind.
    Altınay S; Kural A; Özmen A; Tural D; Tutar Y
    Anticancer Agents Med Chem; 2023; 23(3):298-305. PubMed ID: 35692151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.
    Serova M; Bieche I; Sablin MP; Pronk GJ; Vidaud M; Cvitkovic E; Faivre S; Raymond E
    Br J Cancer; 2011 Jan; 104(2):272-80. PubMed ID: 21179031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
    Ryu Tiger YK; Jain S; Barta SK; Tolu S; Estrella B; Sawas A; Lue JK; Francescone MM; Pro B; Amengual JE
    Leuk Lymphoma; 2024 Jun; 65(6):736-745. PubMed ID: 38517235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
    Marchi E; O'Connor OA
    Ther Adv Hematol; 2012 Aug; 3(4):227-35. PubMed ID: 23606933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
    Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
    Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.
    Azzoli CG; Krug LM; Gomez J; Miller VA; Kris MG; Ginsberg MS; Henry R; Jones J; Tyson L; Dunne M; Pizzo B; Farmer A; Venkatraman E; Steffen R; Sirotnak FM
    Clin Cancer Res; 2007 May; 13(9):2692-8. PubMed ID: 17473201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use.
    O'Connor OA; Amengual J; Colbourn D; Deng C; Sawas A
    Leuk Lymphoma; 2017 Nov; 58(11):2548-2557. PubMed ID: 28738754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate.
    Foss FM; Parker TL; Girardi M; Li A
    Leuk Lymphoma; 2019 Dec; 60(12):2927-2930. PubMed ID: 31119966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy.
    Koch E; Story SK; Geskin LJ
    Leuk Lymphoma; 2013 Nov; 54(11):2448-51. PubMed ID: 23442065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
    Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
    Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pralatrexate Monitoring Using a Commercially Available Methotrexate Assay to Avoid Potential Drug Interactions.
    McPherson JP; Vrontikis A; Sedillo C; Halwani AS; Gilreath JA
    Pharmacotherapy; 2016 Feb; 36(2):e8-e11. PubMed ID: 26809959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.